GSA Capital Partners LLP cut its position in shares of Curis, Inc. (NASDAQ:CRIS) by 82.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 342,022 shares of the biotechnology company’s stock after selling 1,571,186 shares during the period. GSA Capital Partners LLP’s holdings in Curis were worth $592,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CRIS. LMR Partners LLP purchased a new position in Curis during the second quarter valued at $124,000. Candriam Luxembourg S.C.A. purchased a new position in shares of Curis in the first quarter worth about $523,000. Sio Capital Management LLC purchased a new position in shares of Curis in the first quarter worth about $545,000. Finally, Arnhold LLC acquired a new stake in Curis during the first quarter worth about $1,907,000. 33.52% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CRIS stock opened at $1.62 on Friday. The company has a debt-to-equity ratio of 4.43, a current ratio of 3.01 and a quick ratio of 3.01. Curis, Inc. has a fifty-two week low of $1.36 and a fifty-two week high of $9.40.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. The firm had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.41 million. Curis had a negative net margin of 407.29% and a negative return on equity of 225.77%. sell-side analysts predict that Curis, Inc. will post -1.18 EPS for the current year.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Curis from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Cowen reiterated a “buy” rating on shares of Curis in a research report on Monday, August 6th. SunTrust Banks dropped their price target on shares of Curis to $8.00 and set a “buy” rating for the company in a research report on Friday, August 3rd. Finally, ValuEngine cut shares of Curis from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $18.75.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Read More: What is Compound Annual Growth Rate (CAGR)?

Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS).

Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.